HSIN-AN HOUTang, Chao-HsiunChao-HsiunTangGoh, Choo HuaChoo HuaGohShen, Shih-PeiShih-PeiShenHuang, Kuan-ChihKuan-ChihHuangQiu, HongHongQiuSiggins, SarahSarahSigginsRothwell, Lee AnneLee AnneRothwellLiu, YanfangYanfangLiu2023-09-142023-09-142022-09-212045-2322https://pubmed.ncbi.nlm.nih.gov/36131079/https://scholars.lib.ntu.edu.tw/handle/123456789/635378The incidence rate of AL (light-chain) amyloidosis is not known in Asia. We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database and Death Registry to estimate incidence and all-cause case fatality rates, and characteristics of patients with AL amyloidosis in Taiwan. All patients with confirmed, newly diagnosed AL amyloidosis from 01-Jan-2016 until 31-Dec-2019 were enrolled and followed up until dis-enrolment, death or study end (31-Dec-2019). There were 841 patients with newly diagnosed AL amyloidosis with median age of 61.4 years and 58.7% were men. At diagnosis, cardiac, renal and liver-related diseases were present in 28.54%, 23.19% and 2.14% of patients, respectively. AL amyloidosis age-adjusted annual incidence was 5.73 per million population in 2016 and 5.26 per million population in 2019. All-cause case fatality ranged from 1.7 to 2.9% over the study period and was highest (~10%) in patients ≥ 80 years. Survival was significantly lower in patients with co-morbid cardiac, renal, or liver-related diseases which could indicate organ involvement. The incidence of AL amyloidosis in Taiwan appears to be similar to Western countries. The poor prognosis in patients with co-morbid diseases highlights the need for earlier diagnosis.en[SDGs]SDG3journal article10.1038/s41598-022-18990-336131079361310792-s2.0-85138254279https://api.elsevier.com/content/abstract/scopus_id/85138254279